Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
AbbVie: A 4% Yield Plus Potential Upside - What's Not To Like?
01:00pm, Friday, 10'th Feb 2023
We share another of the 22 Mega Cap stocks with the prospect of higher prices in 2023. Lyn Alden provides important insight into the fundamental terrain on which AbbVie Inc. currently sits.
AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected
10:52am, Friday, 10'th Feb 2023
AbbVie stock won at least one upgrade Friday after issuing long-awaited guidance for Humira for the first year it faces new competition. The post AbbVie's Humira: The Downfall Won't Be As 'Draconian'
Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics
10:32am, Friday, 10'th Feb 2023
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare
AbbVie Inc. (ABBV) Q4 2022 Earnings Call Transcript
05:02pm, Thursday, 09'th Feb 2023
AbbVie Inc. (NYSE:ABBV ) Q4 2022 Earnings Conference Call February 9, 2023 9:00 AM ET Company Participants Liz Shea - Vice President of Investor Relations Rick Gonzalez - Chairman & Chief Executive Of
Pharmaceutical companies losing patent protection as competition grows
03:34pm, Thursday, 09'th Feb 2023
The Wall Street Journal's Jared Hopkins joins 'Power Lunch' to discuss biotech patent protection duration, competition coming to the pharmaceutical industry and pharmaceutical M&A plans.
The End of Abbvie's $200 Billion Monopoly Won't Sink the Stock
12:58pm, Thursday, 09'th Feb 2023
The drugmaker is offering steep discounts on its immune-disease therapy Humira to protect market share this year.
What Stocks to Buy Today? 3 Dividend Stocks To Watch After Earnings
12:53pm, Thursday, 09'th Feb 2023
Are these the best dividend stocks to buy today?
AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales
12:49pm, Thursday, 09'th Feb 2023
AbbVie's Q4 earnings (ABBV) beat estimates, while sales miss the same. Full-year 2023 EPS falls short of estimates.
AbbVie (ABBV) Q4 Earnings Beat Estimates
10:34am, Thursday, 09'th Feb 2023
AbbVie (ABBV) delivered earnings and revenue surprises of 1.69% and 1.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Do Humira Biosimilars Threaten AbbVie's Dividend?
09:10am, Thursday, 09'th Feb 2023
Generic competition will eat at Humira's roughly $20 billion in annual sales.
AbbVie Posts an Earnings Beat but Forecast Misses as Competition Intensifies
08:47am, Thursday, 09'th Feb 2023
AbbVie says international sales of Humira in the fourth quarter fell 26.5% from a year earlier.
AbbVie's stock gains on Q4 results
08:04am, Thursday, 09'th Feb 2023
Shares of AbbVie Inc. ABBV, -0.37% gained 2.4% in premarket trading on Thursday after the company beat earnings expectations for the fourth quarter of 2022. AbbVie had a profit of $2.4 billion, or $1.
4 Dividend Aristocrat Buys For February
08:30am, Wednesday, 08'th Feb 2023
"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. By yield, VFC topped all Aristocrats. Top-ten yiel
Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings?
01:33pm, Tuesday, 07'th Feb 2023
AbbVie's (ABBV) fourth-quarter performance is expected to reflect the impact of strong demand for immunology and neuroscience products.
Hedge Funds Love These 8 Dividend Blue Chips, And So Should You
07:15am, Tuesday, 07'th Feb 2023
Hedge funds employ some of the world's brightest analysts, with the most resources for analyzing companies. Lists of the most widely owned blue-chips among hedge funds can be a good source of new inve
